Lonza in deal to manufacture Cellectis’ UCART oncology pipeline 03-Oct-2019 By Vassia Barba Cellectis chooses Lonza to take on the clinical manufacturing of its UCART blood cancer immunotherapy candidates, intended to be marketed as industrialized, readily available CAR-T cells.